IL93242A - Pharmaceutical preparation for the treatment of beta-streptococcal tonsillitis comprising a streptococcus strain - Google Patents
Pharmaceutical preparation for the treatment of beta-streptococcal tonsillitis comprising a streptococcus strainInfo
- Publication number
- IL93242A IL93242A IL9324290A IL9324290A IL93242A IL 93242 A IL93242 A IL 93242A IL 9324290 A IL9324290 A IL 9324290A IL 9324290 A IL9324290 A IL 9324290A IL 93242 A IL93242 A IL 93242A
- Authority
- IL
- Israel
- Prior art keywords
- ncib
- strains
- streptococci
- treatment
- pharmaceutical preparation
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 206010044013 Tonsillitis streptococcal Diseases 0.000 title claims abstract description 23
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 15
- 241000194017 Streptococcus Species 0.000 title description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 244000005700 microbiome Species 0.000 claims abstract description 22
- 238000011321 prophylaxis Methods 0.000 claims abstract description 14
- 241000194023 Streptococcus sanguinis Species 0.000 claims abstract description 11
- 241001134658 Streptococcus mitis Species 0.000 claims abstract description 9
- 230000035899 viability Effects 0.000 claims abstract description 8
- 206010044008 tonsillitis Diseases 0.000 claims description 13
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000020477 pH reduction Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 229930195708 Penicillin V Natural products 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 229940056367 penicillin v Drugs 0.000 description 3
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 101100218662 Felis catus GLB1 gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- 241000394605 Viola striata Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010001093 acute tonsillitis Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- CQTZJAKSNDFPOB-UHFFFAOYSA-N 2-naphthyl dihydrogen phosphate Chemical compound C1=CC=CC2=CC(OP(O)(=O)O)=CC=C21 CQTZJAKSNDFPOB-UHFFFAOYSA-N 0.000 description 1
- DYFLEINNYRXWNC-UHFFFAOYSA-N 3-hydroxybutan-2-one;2-oxopropanoic acid Chemical compound CC(O)C(C)=O.CC(=O)C(O)=O DYFLEINNYRXWNC-UHFFFAOYSA-N 0.000 description 1
- JIEINYQEXWLMCU-UHFFFAOYSA-N 7-bromo-3-hydroxy-n-(2-methoxyphenyl)naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1O JIEINYQEXWLMCU-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JWHURRLUBVMKOT-HNNXBMFYSA-N L-leucine 2-naphthylamide Chemical compound C1=CC=CC2=CC(NC(=O)[C@@H](N)CC(C)C)=CC=C21 JWHURRLUBVMKOT-HNNXBMFYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8900510A SE463349B (sv) | 1989-02-15 | 1989-02-15 | Farmaceutiskt preparat foer profylax mot och/eller behandling av beta-streptokockinducerad tonsillit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL93242A0 IL93242A0 (en) | 1990-11-29 |
| IL93242A true IL93242A (en) | 1994-11-28 |
Family
ID=20375049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9324290A IL93242A (en) | 1989-02-15 | 1990-02-01 | Pharmaceutical preparation for the treatment of beta-streptococcal tonsillitis comprising a streptococcus strain |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5378459A (cs) |
| EP (1) | EP0458855B1 (cs) |
| CN (1) | CN1046099A (cs) |
| AR (1) | AR247099A1 (cs) |
| AT (1) | ATE142503T1 (cs) |
| AU (1) | AU628493B2 (cs) |
| CA (1) | CA2047189A1 (cs) |
| CS (1) | CS74890A2 (cs) |
| DD (1) | DD291926A5 (cs) |
| DE (1) | DE69028520T2 (cs) |
| DK (1) | DK0458855T3 (cs) |
| EG (1) | EG19075A (cs) |
| ES (1) | ES2091818T3 (cs) |
| FI (1) | FI101452B1 (cs) |
| GR (1) | GR1000639B (cs) |
| HU (1) | HU209915B (cs) |
| IE (1) | IE900459L (cs) |
| IL (1) | IL93242A (cs) |
| IS (1) | IS1678B (cs) |
| MY (1) | MY106487A (cs) |
| NO (1) | NO178883C (cs) |
| NZ (1) | NZ232381A (cs) |
| PH (1) | PH27203A (cs) |
| PT (1) | PT93141A (cs) |
| SE (1) | SE463349B (cs) |
| WO (1) | WO1990009186A1 (cs) |
| YU (1) | YU23490A (cs) |
| ZA (1) | ZA90692B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705152A (en) * | 1990-10-26 | 1998-01-06 | Interprise Limited | Antimicrobial composition |
| AUPN698495A0 (en) * | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
| SE511648C2 (sv) * | 1998-04-17 | 1999-11-01 | Bacterum Ab | Streptokockpreparat för behandling av öroninflammation |
| ES2286038T3 (es) * | 1999-10-12 | 2007-12-01 | Blis Technologies Limited | Lantibiotico. |
| DE10139039A1 (de) * | 2001-08-08 | 2003-05-08 | Zinon Douvlis | Medikamentöse Suppression maligner Proliferationsprozesse durch Aminosäuren und Aminosäurenbindungen orientierte Reaktionen |
| US20110256179A1 (en) | 2008-11-17 | 2011-10-20 | Essum Ab | Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains |
| US10863753B2 (en) | 2015-10-01 | 2020-12-15 | The Governing Council Of The University Of Toronto | Iron-fortified tea preparations and methods of making same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1195613A (en) * | 1981-02-17 | 1985-10-22 | Forsyth Dental Infirmary For Children | Method of treating periodontosis |
| US4454109A (en) * | 1981-02-17 | 1984-06-12 | Forsyth Dental Infirmary For Children | Method of treating periodontosis |
| JPS5927833A (ja) * | 1982-08-06 | 1984-02-14 | Advance Res & Dev Co Ltd | コレステロール乃至トリグリセリド低下剤 |
-
1989
- 1989-02-15 SE SE8900510A patent/SE463349B/sv not_active IP Right Cessation
-
1990
- 1990-01-30 ZA ZA90692A patent/ZA90692B/xx unknown
- 1990-02-01 IL IL9324290A patent/IL93242A/en not_active IP Right Cessation
- 1990-02-05 NZ NZ232381A patent/NZ232381A/en unknown
- 1990-02-07 YU YU23490A patent/YU23490A/sh unknown
- 1990-02-08 PH PH40021A patent/PH27203A/en unknown
- 1990-02-09 IE IE900459A patent/IE900459L/xx unknown
- 1990-02-12 AT AT90903444T patent/ATE142503T1/de not_active IP Right Cessation
- 1990-02-12 GR GR900100092A patent/GR1000639B/el unknown
- 1990-02-12 CA CA002047189A patent/CA2047189A1/en not_active Abandoned
- 1990-02-12 ES ES90903444T patent/ES2091818T3/es not_active Expired - Lifetime
- 1990-02-12 DK DK90903444.9T patent/DK0458855T3/da active
- 1990-02-12 EP EP90903444A patent/EP0458855B1/en not_active Expired - Lifetime
- 1990-02-12 HU HU901920A patent/HU209915B/hu not_active IP Right Cessation
- 1990-02-12 WO PCT/SE1990/000089 patent/WO1990009186A1/en not_active Ceased
- 1990-02-12 DE DE69028520T patent/DE69028520T2/de not_active Expired - Fee Related
- 1990-02-12 AU AU51577/90A patent/AU628493B2/en not_active Ceased
- 1990-02-13 EG EG7290A patent/EG19075A/xx active
- 1990-02-14 DD DD90337852A patent/DD291926A5/de unknown
- 1990-02-14 PT PT93141A patent/PT93141A/pt not_active Application Discontinuation
- 1990-02-14 IS IS3547A patent/IS1678B/is unknown
- 1990-02-15 MY MYPI90000256A patent/MY106487A/en unknown
- 1990-02-15 AR AR90316173A patent/AR247099A1/es active
- 1990-02-15 CS CS90748A patent/CS74890A2/cs unknown
- 1990-02-15 CN CN90101773A patent/CN1046099A/zh active Pending
-
1991
- 1991-08-13 NO NO913162A patent/NO178883C/no not_active IP Right Cessation
- 1991-08-14 FI FI913845A patent/FI101452B1/fi active
-
1994
- 1994-02-10 US US08/194,753 patent/US5378459A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roos et al. | Interfering α-streptococci as a protection against recurrent streptococcal tonsillitis in children | |
| US4746512A (en) | Anticariogenic or antiperiodontitic agent | |
| Falck et al. | Tolerance and efficacy of interfering alpha-streptococci in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study | |
| Rummens et al. | In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents | |
| AU2003206479A1 (en) | Antimicrobial composition | |
| Brook et al. | The treatment of the carrier state of group A beta-hemolytic streptococci with clindamycin | |
| Ledbetter et al. | The aerobic and anaerobic flora of rattlesnake fangs and venom: therapeutic implications | |
| US5378459A (en) | Pharmaceutical preparation in the treatment of tonsillitis | |
| WO2019013401A1 (ko) | 락토바실러스 루테리 cs 132(kctc 11452bp) 또는 이의 배양물을 포함하는 구강병원균 억제조성물 | |
| CN117599154B (zh) | 含有乳杆菌菌株和乳酸菌素的组合物及其用途 | |
| Buu-Hoi et al. | Endocarditis caused by Capnocytophaga ochracea | |
| Kaufhold et al. | Endocarditis caused by Gemella haemolysans | |
| LeProwse et al. | Catheter-related bacteremia caused by Oerskovia turbata | |
| Moorhouse et al. | Hospital study of transferable drug resistance | |
| Da Costa et al. | Empyema thoracis and lung abscess due to Gemella morbillorum | |
| Aly et al. | Bacterial interference among Staphylococcus aureus strains | |
| Hoppe et al. | Susceptibility of Bordetellapertussis and Bordetellaparapertussis to 24 Antibiotics | |
| US3925160A (en) | Method of producing an antibiotic | |
| JPS6069022A (ja) | 免疫調整剤及びその製造法 | |
| Lentino et al. | Comparative efficacy of cefotiam versus cephalothin in the therapy of skin and soft tissue infections | |
| JPH04503511A (ja) | 扁桃炎治療用薬学的調製物 | |
| Devuyst et al. | Rarity and potential severity of Gemella haemolysans endocarditis | |
| Babiker et al. | Pseudomonas aeruginosa in diabetic foot infections, Gadarif Diabetic Center, Sudan (2017-2018) | |
| Scheifele et al. | Potential significance of colonization with beta-lactamase-producing Haemophilus parainfluenzae in children | |
| Jeffries et al. | Comparative sensitivities to antimicrobial agents of Campylobacter pylori and the gastric campylobacter like organism from the ferret |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |